Description
NLG919 is an inhibitor of indoleamine-2,3-dioxygenase (IDO). This compound displays anticancer chemotherapeutic activity, prolonging survival rates in animal models of glioblastoma.
Product Unit Size | Cost | Quantity | Stock |
---|
NLG919 is an inhibitor of indoleamine-2,3-dioxygenase (IDO). This compound displays anticancer chemotherapeutic activity, prolonging survival rates in animal models of glioblastoma.
Cas No. | 1402836-58-1 |
---|---|
Purity | ≥98% |
Formula | C18H22N2O |
Formula Wt. | 282.39 |
Chemical Name | 1-Cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol |
IUPAC Name | 1-Cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol |
Synonym | NLG919 (GDC-0919), GTPL9019 |
Solubility | Ethanol 30 mg/mL (106.23 mM) DMSO 15 mg/mL warmed (53.11 mM) Water Insoluble |
Store Temp | -20°C |
---|---|
Ship Temp | Ambient |
MSDS | |
---|---|
Info Sheet |
Vacchelli E, Aranda F, Eggermont A, et al. Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology. 2014 Dec 15;3(10):e957994. PMID: 25941578.
Li M, Bolduc AR, Hoda MN, et al. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. J Immunother Cancer. 2014 Jul 7;2:21. PMID: 25054064.
Peptide, GnRH analog.
5-HT1A partial agonist, 5-HT2C antagonist.
Synthetic ITC.
Building block
Diterpene found in brewed, unfiltered coffee; F...
Endogenous opioid peptide; μOr agonist.
PERK inhibitor.
Endogenous APP peptide cleavage product, primar...
Hydrazine; L-amino acid decarboxylase inhibitor...
Diphenylmethane derivative, stimulates colonic ...
Protease inhibitor.
Endogenous peptide hormone; GnRH agonist.
ATP competitive CDK inhibitor.
Synthetic hydrocortisone derivative; glucocorti...
Fermentation impurity
1,8-Diaza-anthracene-tetrone; JNK and ERK5 inhi...
FIASMA, SERT and NET inhibitor, mAChR antagonis...
Flavonoid found in fruits, vegetables, and grai...
Endogenous steroid hormone, estriol precursor; ...
Endogenous neuropeptide, also known as substanc...